Durvalumab
Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
AstraZenecamonoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Kling Biotherapeutics B.V. | Phase 1/2 | B |
Evomela University of Washington | Phase 2 | B |
Cladribine University of Washington | Phase 2 | B |
FILGRASTIM University of Washington | Phase 2 | B |
CYCLOSPORIN A University of Washington | Phase 2 | B |
View all 18 →
Same molecule, other indications
Durvalumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →